Bh3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
HIGHLIGHTS who: Narissa Parry from the (UNIVERSITY) have published the research: BH3 mimetics in combination with nilotinib or ponatinib represent […]